SCHEMBL15096232

SCHEMBL15096232

C=C(NCC(C)C)c1cccnn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.44
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 5/20 0.37
MEN1 O00255 3/20 0.37
MAPT P10636 1/20 0.37
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CES1 P23141 1/20 0.35
HPGD P15428 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HCRTR2 O43614 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33
AHR P35869 1/20 0.33
FAAH O00519 1/20 0.33
NPC1 O15118 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15096236 0.81 ALDH1A1 (0.53) ALDH1A1KMT2AMEN1MAPTGAA
SCHEMBL26896049 0.78 P2RX7 (0.43) P2RX7KMT2AMEN1GAACES1
SCHEMBL24267395 0.74 P2RX7 (0.44) P2RX7ALDH1A1KMT2AMEN1CES1
SCHEMBL15096233 0.71 KMT2A (0.48) ALDH1A1KMT2AMEN1GAAHSD17B10
SCHEMBL15096231 0.71 P2RX7 (0.44) P2RX7ALDH1A1KMT2AMEN1MAPT
SCHEMBL15096235 0.69 NAMPT (0.43) ALDH1A1KMT2AGAAHSD17B10HPGD
SCHEMBL23586567 0.69
SCHEMBL15096230 0.69 HCAR2 (0.39) ALDH1A1KMT2AMEN1MAPTGAA
SCHEMBL14152209 0.68 P2RX7 (0.51) P2RX7KMT2AMEN1CES1LMNA
SCHEMBL16259081 0.67 GOT1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975232-B2 Macrocyclic kinase inhibitors and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2015-03-10 US disclosed
US-20130178429-A1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178429-A1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF MAP3K20, MAP3K11, MAP3K1 P2RX7 2779/4885ALDH1A1 3932/4885KMT2A 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.